Pseudomonas aeruginosa bacteraemia: independent risk factors for mortality and impact of resistance on outcome
- 1 December 2014
- journal article
- Published by Microbiology Society in Journal of Medical Microbiology
- Vol. 63 (12), 1679-1687
- https://doi.org/10.1099/jmm.0.073262-0
Abstract
The rates of multidrug-resistant, extensively drug-resistant and pandrug-resistant isolates amongst non-fermenting Gram-negative bacilli, particularlyPseudomonas aeruginosa, have risen worldwide. The clinical consequence of resistance and the impact of adverse treatment on the outcome of patients withP. aeruginosabacteraemia remain unclear. To better understand the predictors of mortality, the clinical consequence of resistance and the impact of inappropriate therapy on patient outcomes, we analysed the first episode ofP. aeruginosabacteraemia in patients from a Brazilian tertiary-care hospital during the period from May 2009 to August 2011. Antimicrobial susceptibility testing was conducted; phenotypic detection of metallo-β-lactamase (MBL) and PCR of MBL genes were performed on carbapenem-resistant strains. Amongst the 120P. aeruginosaisolates, 45.8 % were resistant to carbapenem and 36 strains were tested for MBL detection. A total of 30 % were phenotypically positive and, of these, 77.8 % expressed an MBL gene,blaSPM-1(57 %) andblaVIM-type (43 %). The resistance rates to ceftazidime, cefepime, piperacillin/tazobactam, carbapenem, fluoroquinolone and aminoglycoside were 55, 42.5, 35, 45.8, 44 and 44 %, respectively. Previous antibiotic use, length of a hospital stay ≥30 days prior toP. aeruginosa, haemodialysis, tracheostomy, pulmonary source of bacteraemia and Intensive Care Unit admission were common independent risk factors for antimicrobial resistance. Cefepime resistance, multidrug resistance and extensive drug resistance were independently associated with inappropriate therapy, which was an important predictor of mortality, being synergistic with the severity of the underlying disease.Keywords
This publication has 31 references indexed in Scilit:
- Hospital costs of nosocomial multi-drug resistant Pseudomonas aeruginosa acquisitionBMC Health Services Research, 2012
- Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistanceClinical Microbiology & Infection, 2012
- Prospective Multicenter Study of the Impact of Carbapenem Resistance on Mortality in Pseudomonas aeruginosa Bloodstream InfectionsAntimicrobial Agents and Chemotherapy, 2012
- Secretion of Pseudomonas aeruginosa type III cytotoxins is dependent on pseudomonas quinolone signal concentrationMicrobial Pathogenesis, 2010
- Impact of multidrug-resistantPseudomonas aeruginosainfection on patient outcomesExpert Review of Pharmacoeconomics & Outcomes Research, 2010
- Efflux pumps expression and its association with porin down-regulation and β-lactamase production among Pseudomonas aeruginosa causing bloodstream infections in BrazilBMC Microbiology, 2010
- CDC/NHSN surveillance definition of health care–associated infection and criteria for specific types of infections in the acute care settingAmerican Journal of Infection Control, 2008
- Dynamics of Pseudomonas aeruginosa genome evolutionProceedings of the National Academy of Sciences of the United States of America, 2008
- Molecular Epidemiology of Pseudomonas aeruginosa in the Intensive Care Units - A ReviewThe Open Microbiology Journal, 2007
- Predictors of 30-Day Mortality among Patients with Pseudomonas aeruginosa Bloodstream Infections: Impact of Delayed Appropriate Antibiotic SelectionAntimicrobial Agents and Chemotherapy, 2007